Publicaciones en colaboración con investigadoras/es de Hospital Universitario La Paz (25)

2023

  1. Decoding the molecular heterogeneity of pediatric monomorphic post–solid organ transplant lymphoproliferative disorders

    Blood, Vol. 142, Núm. 5, pp. 434-445

2022

  1. Clinical spectrum of COVID-19 and risk factors associated with severity in Spanish children

    European journal of pediatrics, Vol. 181, Núm. 3, pp. 1105-1115

  2. Current status of precision medicine in pediatric oncology in Spain: a consensus report by the Spanish Society of Paediatric Haematology and Oncology (SEHOP)

    Clinical and Translational Oncology, Vol. 24, Núm. 5, pp. 809-815

  3. Langerhans cell histiocytosis. Advances in pathogenesis and clinical practice

    Anales de Pediatria, Vol. 97, Núm. 2, pp. 130.e1-130.e7

  4. Tapering of the thrombopoietin receptor agonist in paediatric patients with chronic immune thrombocytopenia: Is it possible?

    British Journal of Clinical Pharmacology, Vol. 88, Núm. 9, pp. 4220-4223

2021

  1. Diagnostic Accuracy of the Panbio Severe Acute Respiratory Syndrome Coronavirus 2 Antigen Rapid Test Compared with Reverse-Transcriptase Polymerase Chain Reaction Testing of Nasopharyngeal Samples in the Pediatric Population

    Journal of Pediatrics, Vol. 232, pp. 287-289.e4

2020

  1. Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARS-CoV-2 pandemic

    Pediatric Blood and Cancer

  2. Role of rs10406069 in miR-5196 in hyperdiploid childhood acute lymphoblastic leukemia

    Epigenomics, Vol. 12, Núm. 22, pp. 1949-1955

  3. Study protocol for a phase II, multicentre, prospective, non-randomised clinical trial to assess the safety and efficacy of infusing allogeneic activated and expanded natural killer cells as consolidation therapy for paediatric acute myeloblastic leukaemia

    BMJ Open, Vol. 10, Núm. 1

2018

  1. Involvement of SNPs in miR-3117 and miR-3689d2 in childhood acute lymphoblastic leukemia risk

    Oncotarget, Vol. 9, Núm. 33, pp. 22907-22914

  2. Involvement of miRNA polymorphism in mucositis development in childhood acute lymphoblastic leukemia treatment

    Pharmacogenomics, Vol. 19, Núm. 18, pp. 1403-1412

  3. Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia

    Pharmacogenomics Journal, Vol. 18, Núm. 6, pp. 704-712

  4. Pharmacoepigenetics in childhood acute lymphoblastic leukemia: Involvement of miRNA polymorphisms in hepatotoxicity

    Epigenomics, Vol. 10, Núm. 4, pp. 409-417

2017

  1. Confirmation of involvement of new variants at CDKN2A/B in pediatric acute lymphoblastic leukemia susceptibility in the Spanish population

    PLoS ONE, Vol. 12, Núm. 5

  2. Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome

    Journal of Pediatrics, Vol. 189, pp. 72-78.e3

  3. Early clinical trials in paediatric oncology in Spain: a nationwide perspective

    Anales de Pediatria, Vol. 87, Núm. 3, pp. 155-163

2016

  1. High Body Mass Index as a Risk Factor for Hospitalization Due to Influenza: A Case-Control Study

    Archivos de Bronconeumologia, Vol. 52, Núm. 6, pp. 299-307

  2. Landscape of early clinical trials for childhood and adolescence cancer in Spain

    Clinical and Translational Oncology, Vol. 18, Núm. 7, pp. 708-713

  3. MIR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia

    Pharmacogenetics and Genomics, Vol. 26, Núm. 11, pp. 517-525

  4. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia

    Pharmacogenomics, Vol. 17, Núm. 7, pp. 731-741